| 5.7 -0.02 (-0.35%) | 05-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.06 | 1-year : | 7.72 |
| Resists | First : | 6.04 | Second : | 6.61 |
| Pivot price | 6.02 |
|||
| Supports | First : | 5.13 | Second : | 4.26 |
| MAs | MA(5) : | 5.74 |
MA(20) : | 6.01 |
| MA(100) : | 5.62  |
MA(250) : | 3.9 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 8.5 |
D(3) : | 8 |
| RSI | RSI(14): 45.8 |
|||
| 52-week | High : | 7.17 | Low : | 1.6 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ANNX ] has closed above bottom band by 19.6%. Bollinger Bands are 21.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.84 - 5.87 | 5.87 - 5.9 |
| Low: | 5.55 - 5.6 | 5.6 - 5.63 |
| Close: | 5.64 - 5.71 | 5.71 - 5.76 |
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Wed, 06 May 2026
Annexon CEO to speak May 13; webcast replay stays up 30 days - Stock Titan
Wed, 06 May 2026
Annexon to Present at the Bank of America Securities Health Care Conference 2026 - ChartMill
Fri, 01 May 2026
ANNX Earnings History & Surprises | EPS & Revenue Results | ANNEXON INC (NASDAQ:ANNX) - ChartMill
Sun, 26 Apr 2026
Wall Street analysts see a 165.52% upside in Annexon (ANNX): Can the stock really move this high? - MSN
Sun, 26 Apr 2026
Annexon (ANNX): 7 Small Cap Stocks with the Highest Upside Potential - Yahoo Finance
Tue, 21 Apr 2026
Annexon Biosciences (ANNX) Buy Rating Retained - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 163 (M) |
| Shares Float | 131 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 93 (%) |
| Shares Short | 19,680 (K) |
| Shares Short P.Month | 16,400 (K) |
| EPS | -1.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.41 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -43.1 % |
| Return on Equity (ttm) | -82 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.32 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -186 (M) |
| Levered Free Cash Flow | -104 (M) |
| PE Ratio | -4.26 |
| PEG Ratio | 0 |
| Price to Book value | 4.01 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|